Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURMOUNT-1: Tirzepatide in Obesity and Overweight
NCT04184622Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2019
- Primary completion
- Apr 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
A Phase 3 trial of tirzepatide in obesity, Overweight, sponsored by Eli Lilly and Company. Started Dec 2019; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT04184622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04184622.